UNASSIGNED: @entity2142 in @entity7965 ( @entity7965 ) can effectively be controlled with eculizumab, a humanized monoclonal antibody that binds complement protein C5. We report here a retrospective comparison study between 123 @entity1 treated with eculizumab in the recent period (>2005) and 191 historical controls (from the French registry). Overall survival (OS) at six years was 92% (95%CI, 87 to 98) in the eculizumab cohort versus 80% (95%CI 70 to 91) in historical controls diagnosed after 1985 (HR 0.38 [0.15 to 0.94], p=0.037). There were significantly fewer @entity715 events (TEs) in the group of @entity1 treated with eculizumab (4% [1-10]) as compared to the historical cohort (27% [20-34]). However, we found that TEs may still occur after the initiation of eculizumab treatment and that previous TEs still have a negative impact on survival. Evolutions to @entity2590 or @entity3052 were similar in both cohorts. There was less evolution to @entity2150 in the treatment group. In multivariate analysis, absence of a previous TE and treatment with eculizumab were associated with a better OS. Treatment with eculizumab improves overall survival in classic @entity7965 @entity1 without increasing the risk of @entity2214 . This article is protected by copyright. All rights reserved.

Impact of eculizumab treatment on XXXX : A treatment versus no-treatment study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2214 :: ('MESH:D007945', 'Disease') :: ['clonal evolution'] @entity2150 :: ('MESH:D000741', 'Disease') :: ['aplastic anemia'] @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndrome'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute leukemia'] @entity7965 :: ('MESH:D006457', 'Disease') :: ['Paroxysmal nocturnal hemoglobinuria', 'PNH'] @entity2142 :: ('MESH:D006461', 'Disease') :: ['Intravascular hemolysis'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombotic']
@entity7965 :: (MESH:D006457,Disease) :: ['paroxysmal nocturnal hemoglobinuria']
